Remus Pharmaceuticals Complete Financial Statements

In FYNone, Remus Pharmaceuticals (REMUS) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 6.1% and ROE of 13.4%. Full financial statements from FY2024 to FY2025 (2 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Remus Pharmaceuticals stock price NSE .

2 Years of Data
2025 - 2024

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 6.08% 2025 data
EBITDA Margin 8.16% 2025 data
Operating Margin 7.00% 2025 data
Return on Assets 8.78% 2025 data
Return on Equity 13.43% 2025 data

Balance Sheet Ratios

Current Ratio 7.62 2025 data
Equity Ratio 65.36% 2025 data
Asset Turnover 1.44 2025 data

REMUS Revenue, Net Profit & EBITDA — Year-on-Year Growth

REMUS YoY (March 2025 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+30.0%
Year-over-Year
Equity Growth
+61.7%
Year-over-Year
Operating Cash Flow Growth
+600.0%
Year-over-Year
Investing Cash Flow Growth
+56.0%
Year-over-Year
Financing Cash Flow Growth
-78.6%
Year-over-Year

REMUS Income Statement — Revenue, EBITDA & Net Profit

Remus Pharmaceuticals revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 6.1%. Explore REMUS value investing to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024
Revenue 0 625 216
Expenses 0 575 184
EBITDA 0 51 32
Operating Profit Margin % 0.00% 7.00% 14.00%
Depreciation 0 2 1
Interest 0 2 1
Profit Before Tax 0 47 30
Tax 0 9 6
Net Profit 0 38 24
Earnings Per Share (₹) 0.00 65.21 42.97

REMUS Balance Sheet — Assets, Liabilities & Shareholders' Equity

REMUS total assets ₹433 Cr, total equity ₹283 Cr, total liabilities ₹ Cr (2025) — ROE 13.4%.

Years Annual Data ₹ Crores
Particulars 2025 2024
ASSETS
Total Assets 433 333
Current Assets 221 212
Fixed Assets 16 14
Capital Work in Progress 0 0
Investments 186 105
Other Assets 231 215
LIABILITIES
Total Liabilities
Current Liabilities 29 17
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 283 175
Share Capital 6 2
Reserves & Surplus 250 156

REMUS Cash Flow Statement — Operating, Investing & Financing

Remus Pharmaceuticals operating cash flow ₹7 Cr, investing ₹-11 Cr, financing ₹6 Cr, net cash flow ₹3 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024
Operating Activities 7 1
Investing Activities -11 -25
Financing Activities 6 28
Net Cash Flow 3 4